Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Oncotarget|November 16, 2020
Targeting breast cancer metabolism with a novel inhibitor of mitochondrial ATP synthesisMyoung Sook Kim, Ramkishore Gernapudi, Yessenia Cedeño Cedeño, et al.
Scientific Reports|May 17, 2020
Allosteric inhibitor of β-catenin selectively targets oncogenic Wnt signaling in colon cancerAnton Cheltsov, Natsuko Nomura, Venkata M Yenugonda, et al.
Nucleic Acids Research|January 5, 2021
Small molecules inhibitors of the heterogeneous ribonuclear protein A18 (hnRNP A18): a regulator of protein translation and an immune checkpointEduardo Solano-Gonzalez, Katherine M Coburn, Wenbo Yu, et al.
Molecular Cancer Therapeutics|January 24, 2026
Chromobox2 inhibition: a novel activity of alisertib, an aurora A kinase inhibitorTomomi M Yamamoto, Ritsuko Iwanaga, Elizabeth R Woodruff, et al.
Cell Death & Disease|May 16, 2025
Cytoplasmic connexin43-microtubule interactions promote glioblastoma stem-like cell maintenance and tumorigenicityJames W Smyth, Sujuan Guo, Lata Chaunsali, et al.
Cancer Research|February 12, 2021
The miR-181a-SFRP4 Axis Regulates Wnt Activation to Drive Stemness and Platinum Resistance in Ovarian CancerAnil Belur Nagaraj, Matthew Knarr, Sreeja Sekhar, et al.
British Journal of Cancer|June 26, 2020
Targeting the ERG oncogene with splice-switching oligonucleotides as a novel therapeutic strategy in prostate cancerLing Li, Lisa Hobson, Laura Perry, et al.
Oncotarget|October 31, 2015
Multiple spatially related pharmacophores define small molecule inhibitors of OLIG2 in glioblastomaIgor F Tsigelny, Rajesh Mukthavaram, Valentina L Kouznetsova, et al.
Molecular Cancer Research : MCR|September 23, 2022
ATF6-Mediated Signaling Contributes to PARP Inhibitor Resistance in Ovarian CancerAlexandra McMellen, Tomomi M Yamamoto, Lubna Qamar, et al.
Pageof 4